Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc.
Your view on SPPH
Overview
What the company does, where it operates, and who runs it.
About Spencer Pharmaceutical Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Maximilien Arella
- Headquarters
- 8 Faneuil Hall Marketplace, Boston, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Maximilien Arella
- Headquarters
- 8 Faneuil Hall Marketplace, Boston, US
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases.
The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications.
It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Spencer Pharmaceutical Inc., and the rating behind it. SPPH last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Spencer Pharmaceutical Inc.. Starting points for Spencer Pharmaceutical Inc.: EPS -$1.10, beta 3.69 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Spencer Pharmaceutical Inc.. Spencer Pharmaceutical Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Spencer Pharmaceutical Inc.. Trailing twelve-month EPS for Spencer Pharmaceutical Inc. stands at -$1.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Spencer Pharmaceutical Inc.. Spencer Pharmaceutical Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Spencer Pharmaceutical Inc. valued side by side against its closest peers. Spencer Pharmaceutical Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Spencer Pharmaceutical Inc., and how their positions are changing. At a $29,436 market value, institutional positions materially move Spencer Pharmaceutical Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Spencer Pharmaceutical Inc. executives and directors. Shares of Spencer Pharmaceutical Inc. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Spencer Pharmaceutical Inc.. Spencer Pharmaceutical Inc. is a $29,436 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Spencer Pharmaceutical Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Spencer Pharmaceutical Inc.. Coverage tracks Spencer Pharmaceutical Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.